Aidan Lynch

Aidan Lynch

Vice President and General Manager, GSK Pharmaceuticals Ireland

Aidan Lynch is Vice President and General Manager of GSK Pharmaceuticals Ireland. Aidan has been with GSK since 2001, initially in Finance and then Commercial. He was appointed General Manager in 2012. He chairs the Board of Trustees of the GSK Ireland Staff Pension Plan.

Aidan sits on the Board of the Irish Pharmaceutical Healthcare Association (IPHA) and is a member of the IPHA Prescription Division Strategy Board. He is Chairman of both the IPHA Market Access Forum, and the Board’s Finance subcommittee. Aidan sits on the Board of the British Irish Chamber of Commerce and is former President of the Chamber. He has also been a Council Member of Dublin Chamber of Commerce since 2012 and is also a member of the Irish Management Institute (IMI) Council. He is a Board member of the children’s charity, Barretstown – a Serious Fun Camp, and sits on a number of board subcommittees.

GSK is one of the world’s leading research-based healthcare companies with one simple mission: to improve the quality of human life by enabling people to do more, feel better and live longer. It has deep ties in Ireland, employing 1,600 people across four different sites and is the fourth largest employer in the pharmaceutical sector.

Professor Luke O’Neill

Professor Luke O’Neill

Chair of Biochemistry, Trinity College Dublin

Professor Luke O’Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. on the pro-inflammatory cytokine IL-1 and innate immune signaling. His research is in the area of the molecular basis to inflammatory diseases, with a particular interest in Toll-like receptors, inflammasomes and metabolic control of inflammatory cell signalling. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence and in 2014 the European Federation of Immunology Societies Medal. He was elected a member of EMBO in 2005. In 2016 he was named by Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology. He is a European Research Council Advanced Grant Holder and is co-founder of 2 Spin-out companies from his lab – Opsona Therapeutics, a drug development company working in the area of Toll-like receptors, and Inflazome, which is developing inhibitors of inflammasomes for inflammatory diseases. He was elected a Fellow of the Royal Society in 2016.

Dr Richard Littlewood

Dr Richard Littlewood

CEO and Founder, applied strategic, UK

Dr. Richard Littlewood is a physician with clinical practice experience and a management consultant who has worked for 15 years addressing strategic and operational issues in health and pharma.

He has experience as a consultant at Bain and has worked in senior roles at Wyeth/ Pfizer in commercial and R&D. He is a UK GMC registered physician, has an MA from Trinity College, Cambridge and is a graduate of the Sloan Masters management program at London Business School. Areas of focus include new market entry and scenario planning, medical regulatory global optimisation, next generation market access challenges and process redesign.

Richard pioneered on biosimilars strategy from 2007 and has extensive experience in many emerging markets. He is an advisor to private equity and investment firms on healthcare and life sciences.

Sandra Gannon

Sandra Gannon

CEO, Teva and Head of Enterprise Health Alliance

In a mere eight years, Teva has become the largest supplier of prescription medicines in Ireland. Sandra has overseen this rapid growth as Teva’s General Manager in Ireland.

Under her leadership, Teva’s reach across the patient, pharmacy, hospital and primary care communities has continued to deepen with the recent acquisition of products from Actavis. It now distributes over 30,000 medicine packs every day, meaning a patient somewhere in Ireland is dispensed a Teva medicine every 3 seconds.

Sandra joined Teva in 2006, follow its acquisition of IVAX, where she worked in senior roles in Ireland, Scandinavia and the UK.

Key to Teva’s organic growth has been the role Sandra and her colleagues have played in healthcare policy. The company has pioneered patient campaigns like understandgenerics.ie, and been a strong advocate for the change to generic medicines. She was a founding member of a new healthcare industry association, the Healthcare Enterprise Alliance set up in 2015 with the purpose of advancing meaningful reforms in the healthcare system, particularly in relation to how Ireland pays for medicines.

A graduate of Dublin City University, Sandra is active at Government and the Health Service Executive levels on medicine reforms. She has developed a range of policy initiatives to improve access to and the affordability of medicines, both for patients and taxpayers. She has identified biosimilars as the next significant innovation in the Irish medicines market, and as a key growth area for Teva.

Jim Power

Jim Power

CEO, Jim Power Economics Ltd

Jim is owner manager of Jim Power Economics Limited, an economic and financial consultancy. In 2013, he co-founded CJP Consultants with economist Chris Johns. Both companies carry out consultancy projects, public speaking, and training for a variety of public and private sector entities. He was Chief Economist to the Friends First Group and was previously Treasury Economist at AIB (1987-1991) and Chief Economist at Bank of Ireland Group Treasury (1995-2000). Jim writes a weekly column in the Examiner and is a frequent contributor to media. He is a frequent speaker at conferences and seminars both in Ireland and overseas. He lectures on the MSc Management at Smurfit School of Business, UCD. Jim is a board member of Agri-Aware and Chairman of Love Irish Food. He is also Chairman of Three Rock Capital Management, an investment firm.

Tommy Fanning

Tommy Fanning

Head of Pharmaceuticals and Food, IDA Ireland

Tommy Fanning is Head of Bio-Pharmaceuticals and Food department at IDA Ireland, the Irish inward investment agency. His background is in business strategy, development and marketing having held multiple business roles across IDA’s Irish and overseas operations. Prior to his current role he was Head of Engineering, Territory Director for IDA in the US with responsibility for the mid-US states while previously acting as Territory Director for Asia-Pacific based in Tokyo.

He previously worked as Head of Business Development in Europe for Deutsche Bank and State Street in their fund services businesses.

In his current role his team are responsible for building the national strategy as it relates to the development of Bio-Pharma. & Food sectors for international companies in Ireland, as part of the broader life sciences mandate which includes medical technologies.

Having written articles and spoken at conferences on the theme of manufacturing in Ireland, there is now a new window of opportunity for investment in Ireland for high-end manufacturing, value-added services and R&D. Manufacturing is fundamental to the future success of the Irish economy through capital investment and high value job creation with a strong regional focus.

Tommy is a graduate in marketing with a professional qualification from the Marketing Institute of Ireland (MII) and also holds diplomas in business strategy & leadership from the Irish Management Institute (IMI) and accounting & finance from the Assoc. of Chartered Certified Accountants (ACCA).

 

Oliver O’Connor

Oliver O’Connor

Chief Executive, Irish Pharmaceutical Healthcare Association

Chief Executive, Irish Pharmaceutical Healthcare Association, representing 45 research-based pharmaceutical companies providing key medicines in Ireland.

He is a former Government Special Advisor, 2001-2010, for Ms Mary Harney in her roles as Tánaiste, Minister for Enterprise, Trade and Employment and Minister for Health and Children. He was central to key initiatives such as the National Treatment Purchase Fund and the Fair Deal Nursing Home Support Scheme. He also contributed to policy on cancer, health insurance and savings in the pharmaceutical supply chain.

From 2010-15, he was a health finance consultant, with a focus on the interaction of commercial strategies and public policy. He had clients among health insurers, public and private hospitals, pharmaceutical companies, new technology providers, logistics providers and industry associations.

He has been a weekly business columnist for the Irish Times and a frequent contributor to the Sunday Business Post, Sunday Independent and the Wall Street Journal Europe.

He has an MBA from Stanford University Graduate School of Business and a first class honours B.A. from University College Dublin.

Brenda Dooley

Brenda Dooley

Founder and Managing Director, AXIS Healthcare Consulting Ltd

Brenda’s company specialises in pricing and reimbursement applications to authorities in the UK and Ireland on behalf of international client organisations.

A highly experienced market access strategist, Brenda held a variety of senior management roles in the pharmaceutical industry over the past 20 years. She has 11 years of experience working in pricing, market access and health technology assessment (HTA) having previously held the role of National Market Access Director for Pfizer.

Brenda has expert knowledge of the Irish and UK healthcare systems and extensive experience in developing high quality HTAs to demonstrate cost effectiveness for submission to agencies such as the NCPE, SMC and AWMSG.

Brenda holds a M.Sc. in Health Economics, a BA (Hons) Business Studies and a Dip. (Hons) in Financial Management. Her research interests include the development of micro costing analysis and models to better inform decision making on the allocation of resources

Derick Mitchell

Derick Mitchell

Chief Executive, IPPOSI

Dr. Derick Mitchell is the Chief Executive of IPPOSI – the Irish Platform for Patient Organisations, Science & Industry.  IPPOSI is a patient-led organisation that works with patients, government, industry, science and academia to put patients at the heart of policy and medicines.

Prior to joining IPPOSI, Derick was Communications Manager with the EU Joint Programme – Neurodegenerative Disease Research (JPND), where he was responsible for developing external communications strategies and supporting stakeholder engagement activities with patient organisations, researchers and industry across Europe.

Derick has over eight years’ experience of management, advocacy, scientific communications and patient/public engagement, through previous positions at both the European and the national level (JPND, BBMRI Stakeholders’ Forum, REMEDI NUI Galway) and has a strong interest in the area of patient and public involvement in research.Derick graduated with a BSc. (Hons) in Biotechnology from NUI Galway (2000) followed by a PhD in Molecular Medicine from University College Dublin (2004).  Outside of IPPOSI, Derick spends his free time attempting to influence his two toddler daughters.

Darragh O’Loughlin

Darragh O’Loughlin

Secretary General, Irish Pharmacy Union

Darragh has experience in both hospital and community pharmacy and has operated his own pharmacy in Galway for the last 17 years. He graduated from Trinity College Dublin in 1993 and registered as a pharmacist in 1994. He also holds qualifications from the Institute of Commercial Management and Henley Business School. Darragh has considerable experience of regulation, quality standards and professional development in pharmacy and healthcare in Ireland and Europe, having previously served on both the Council of the Pharmaceutical Society of Ireland (PSI) and the Board of the Health Information & Quality Authority (HIQA). He is also a former President of the Pharmaceutical Group of the European Union (PGEU), representing approximately 400,000 community pharmacists and 154,000 pharmacies at a European level. Darragh advocates consistently for a greater recognition of the contribution that community pharmacists make to patient health and for an expansion of the role of pharmacists in delivering convenient, accessible and cost-effective healthcare for the benefit of patients, the public and the health system.

Dr. Jayne Crowe

Dr. Jayne Crowe

Director of Human Products Authorisation and Registration, HPRA

Jayne Crowe MB BCh BAO, MRCGP, DRCOG, DCH, DTM, PG Dip. Pharm Med, qualified in medicine from Queen’s University in Belfast. She has worked in clinical medicine both in the hospital setting and as a General Practitioner and is on the Specialist Register of General Practice. She is a member of the Royal College of General Practitioners, an Adjunct Assistant Professor in Pharmaceutical Medicine, Pharmacology and Therapeutics and a member of the Management Committee of the Masters in Pharmaceutical Medicine at Trinity College.

Jayne is a member of the National Committee for Clinical Effectiveness, a Committee member of the Association of Pharmaceutical Physicians of Ireland and a delegate on the European Commission’s Safe and Timely Access to Medicines for Patients’ Committee. Prior to her appointment as Director, Jayne as Clinical Assessment Manager, represented the HPRA at EU level at the Coordination Group for Mutual Recognition and Decentralised procedures (CMDh). She is currently the Chair of the EU Joint Good Clinical Practice Inspectors’ Working Group/CMDh, Working Party

Jean Delaney

Jean Delaney

Partner, PwC

Jean Delaney is a partner in PwC Ireland’s tax practice specialising in the pharmaceutical/life science sector. She leads PwC Ireland’s pharmaceutical/life science practice, a cross-discipline team of 10 partners and 75 staff. The team serve major medical devices and pharmaceutical clients with significant operations in Ireland and abroad.
Jean acts for a number of household names in the pharmaceutical/life science sector including US, UK and Irish headquartered multinationals. Jean has extensive cross border experience which includes direct and indirect tax planning for principal companies and supply chain operations including VAT and customs.